Sutro Biopharma STRO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Sutro Biopharma’s reported figures.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's EBITDA?
- Sutro Biopharma (STRO) reported EBITDA of -$28.38M in Q1 2026.
- How has Sutro Biopharma's EBITDA changed year-over-year?
- Sutro Biopharma's EBITDA increased by 57.4% year-over-year, from -$66.61M to -$28.38M.
- What is the long-term trend for Sutro Biopharma's EBITDA?
- Over 3 years (2021 to 2025), Sutro Biopharma's EBITDA has grown at a 17.3% compound annual growth rate (CAGR), from -$93.68M to -$151.04M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.